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Abstract 
Background: The PI3K/mTOR pathway is commonly de-regulated in human cancer, hence many PI3K 
and mTOR inhibitors have been developed and have now reached clinical trials.  Similarly, CDKs have 
been investigated as cancer drug targets.   
Methods: We have synthesised and characterised a series of 6-aminopyrimidines identified from a 
kinase screen that inhibit PI3K and/or mTOR and/or CDK2.  Kinase inhibition, tumour cell growth, cell 
cycle distribution, cytotoxicity and signalling experiments were undertaken in HCT116 and HT29 
colorectal cancer cell lines, and in vivo HT29 efficacy studies. 
Results: 2,6-Diaminopyrimidines with an O4-cyclohexylmethyl substituent and a C-5 nitroso or cyano 
group (1,2,5) induced cell cycle phase alterations and were growth inhibitory (GI50 < 20 µM). 
Compound 1, but not 2 or 5, potently inhibits CDK2 (IC50 = 0.1 nM) as well as PI3K, and was cytotoxic 
at growth inhibitory concentrations.  Consistent with kinase inhibition data, compound 1 reduced 
phospho-Rb and phospho-rS6 at GI50 concentrations.  Combination of NU6102 (CDK2 inhibitor) and 
pictilisib (GDC-0941; pan PI3K inhibitor) resulted in synergistic growth inhibition, and enhanced 
cytotoxicity in HT29 cells in vitro and HT29 tumour growth inhibition in vivo.   
Conclusion: These studies identified a novel series of mixed CDK2/PI3K inhibitors and demonstrate 
that dual targeting of CDK2 and PI3K can result in enhanced anti-tumour activity. 
 
Keywords: CDK2; PI3K; combination; colorectal; cancer; synergy  
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Introduction 
Insights into the molecular pathology of cancer have resulted in the development of 
targeted approaches for cancer therapy.  The phosphatidylinositol-3-kinase/mammalian target of 
rapamycin (PI3K/mTOR) pathway is one of the most commonly de-regulated pathways in human 
cancer in which signals are transduced via a cascade of lipid and serine/threonine kinases resulting 
in diverse effects on proliferation, apoptosis, protein translation, DNA repair, survival and 
transformation (for review see (Mayer & Arteaga, 2015)).  Activation of receptor tyrosine kinases 
(RTKs) stimulates the PI3K pathway via adapter proteins, and PI3K phosphorylates phosphoinositide-
3,4-biphosphate (PIP2) to generate PIP3 which activates AKT(PKB).  AKT has many functions including 
roles in cell migration, apoptosis and glucose uptake, and the activation of mTOR via down-
regulation of the TSC1/Rheb complex.  mTOR in a complex with Raptor (to form mTORC1) signals via 
p70S6 kinase and 4E-BP1 to regulate the translation of proteins and cell growth. mTOR also 
complexes with Rictor (to form mTORC2) to activate AKT.  Negative feedback occurs at many nodes 
in the PI3K/mTOR cascade, most notably by PTEN and by S6 kinase-mediated regulation of RTK 
signalling, e.g. by downregulation of IRS-1 (Harrington et al, 2005). 
Activating mutations in the PIK3CA (p110α) isoform of PI3 kinase are observed in a wide 
range of tumours including breast, colon, glioblastoma and ovarian cancers (Cancer Genome Atlas 
Research Network, 2008; Mayer & Arteaga, 2015; Stemke-Hale et al, 2008), and inactivation of the 
tumour suppressor protein PTEN has been documented in, amongst others,  glioblastoma, breast 
cancer, prostate cancer and melanoma (Cairns et al, 1997; Cancer Genome Atlas Research Network, 
2008; Celebi et al, 2000; Garcia et al, 1999).  More rarely AKT mutations or amplifications have been 
detected in colorectal, head and neck, pancreatic and breast tumours, and large a proportion of 
cancers have activation of mTORC1 as demonstrated by increased phosphorylation of proteins such 
as S6 kinase, 4EBP1, ribosomal S6 protein and mTOR itself (reviewed in (Menon & Manning, 2008)). 
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Considerable effort has been focussed on the development of PI3K/mTOR pathway 
inhibitors, many of which have now reached clinical trials (Yap et al, 2015).  Rapamycin, discovered 
as an antifungal agent from Streptomyces hygroscopicus, was the first mTOR inhibitor characterised 
and a number of the trial candidates are rapamycin analogues (rapalogues). Rapamycin binds to FK-
binding protein 12 (FKBP12) and therefore only inhibits the mTORC1 complex and not mTORC2.  
Rapamycin has been approved for the treatment of advanced renal cell carcinoma and, following 
promising Phase III trials, the rapalogues temsirolimus and everolimus have been approved for renal 
cell carcinoma and soft tissue/bone sarcomas, respectively (Chiarini et al, 2015).  Additionally, 
compounds are in clinical trials that block both mTORC1 and mTORC2 by competitive inhibition at 
the ATP binding site (Chiarini et al, 2015). 
ATP competitive inhibitors of PI3 kinase have also entered clinical trials (Chiarini et al, 2015).  
These compounds mainly target the p110α isoform of PI3K, but some have been developed that 
have selectivity for other isoforms, e.g. idelalisib inhibits p110δ but not α or β (Lannutti et al, 2011).  
Compounds such as dactolisib target PI3K and mTOR at similar potency, and others such as pictilisib 
are pan PI3K inhibitors (Brachmann et al, 2009).  A review of published early clinical trial data 
indicates that PI3K inhibitors are well tolerated and as single agents they can induce disease 
stabilisation, and in some cases regression (Brachmann et al, 2009; Engelman, 2009).  Pre-clinical 
data suggests that combinations of PI3K inhibitors with other targeted therapies, e.g. MEK inhibitors 
(Engelman et al, 2008; Haagensen et al, 2012; Haagensen et al, 2013), can result in significant 
synergism and clinical trials to explore such combinations are ongoing. 
Cyclin dependent kinases (CDKs) regulate cell cycle progression and transcription via 
sequential interaction with specific cyclins.  In some cancers defects in the expression of CDKs and 
their regulatory proteins, e.g. loss of CDK inhibitors or up-regulation of cyclin expression, leads to 
aberrant regulation of the cell cycle (Satyanarayana & Kaldis, 2009).  CDK2 plays an important role in 
the G1 to S-phase transition and also has a role in S-phase progression.  In particular, 
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phosphorylation of Retinoblastoma protein (Rb) by cyclin D/CDK4 and 6 complexes, followed by the 
cyclin E/CDK2 complex, inactivates Rb releasing E2F and thereby promoting S-phase entry and 
progression (Aleem et al, 2004; Harbour et al, 1999).  Numerous small molecule inhibitors of CDKs 
have been evaluated in clinical trials (Asghar et al, 2015; Shapiro, 2006), some of which are pan-CDK 
inhibitors such as flavopiridol, whereas other compounds are more selective.  Preliminary clinical 
data with CDK inhibitors suggests they are generally well tolerated but rarely induce marked anti-
proliferative toxicity or tumour regressions when given as single agents (Asghar et al, 2015; Shapiro, 
2006).  Thus with the exception of flavopiridol for the treatment of chronic lymphocytic leukaemia 
(Lin et al, 2009), where the transcriptional kinase CDK9 is thought to be the primary target, and 
palbociclib for the management of ER-positive HER2-negative breast cancer, where CDK4/6 is the 
target (Rocca et al, 2014), it has yet to be determined whether CDK-specific or pan-CDK inhibitors 
are preferable (Shapiro, 2006), or indeed if this compound class generally possesses widespread 
anti-tumour activity. 
In a counter-screen of compounds designed to inhibit CDK2 we identified a number of 
molecules that were also mTOR and/or PI3 kinase inhibitors.  These compounds provided an 
opportunity to evaluate the impact of simultaneous modulation of cell cycle and survival/growth 
signalling, via dual CDK and PI3K/mTOR inhibition, which revealed that potent CDK2 inhibition 
combined with PI3K inhibition resulted in cell cycle and growth inhibition, and cytotoxicity.  In vitro 
results with a dual CDK/PI3K inhibitor were recapitulated using a combination of a selective CDK2 
inhibitor (NU6102) and a pan-PI3K inhibitor (pictilisib), and extended to in vivo studies which showed 
enhanced tumour growth inhibition with the drug combination.  
 
  
Dual PI3K/CDK2 inhibition enhances anti-tumour activity 
6 
 
Materials and methods 
Materials 
Dactolisib and pictilisib were purchased from Stratech Scientific (Suffolk, UK) and rapamycin from 
Merck (Nottingham, UK). Anti phospho-4E-BP1 (Cat# 2855S), 4E-BP1 (Cat# 9644), phospho-AKT (Cat# 
4060S), AKT (Cat# 4691S), phospho-ribosomal S6 (Cat# 4858S) and ribosomal S6 (Cat# 2217S) 
antibodies were purchased from NEB (Hitchin, UK). Anti phospho-Rb (Cat# 44-582G) was supplied by 
Invitrogen (Paisley, UK) and anti-Rb (Cat# 554136) by BD Biosciences (Oxford, UK). All other reagents 
were analytical grade where available and supplied by Sigma (Gillingham, UK).  
 
Synthesis of compounds 
The following compounds were synthesised as previously described: 1 (Sayle et al, 2003), 2 (Arris et 
al, 2000), 3 and 4 (Mesguiche et al, 2003), 5 and 6 (Marchetti et al, 2010).  7 and 8 were synthesised 
as described in Supplementary Material. NU6102 (4-[[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino]-
benzenesulfonamide) was synthesised as previously described (Davies et al, 2002). 
 
Enzyme assays 
PI3Ks (Condliffe et al, 2005) and CDK2 (Arris et al, 2000) assays were performed as previously 
described. The inhibition of mTOR kinase activity at 10 µM ATP was measured by TR-FRET according 
to the manufacturer’s instructions 
(http://tools.invitrogen.com/Content/SFS/lanthascreen/PV4753%20FRAP1%20Assay%20Validation.p
df).  
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Cell culture 
HCT116 and HT29 cells were obtained from ATCC (Teddington, UK), and grown in DMEM 
supplemented with 10% (v/v) foetal bovine serum (FBS), 100 units/ml penicillin, 0.1 mg/ml 
streptomycin and 2 mM L-glutamine.  
 
Cell growth inhibition assays 
Cells were trypsinised and plated in 96-well plates at a seeding density of 1000 cells/well.  Twenty 
four hours later cells were incubated for 72 hours with 0.001 - 100 µM of each inhibitor dissolved in 
DMSO with a final DMSO concentration of 1% (v/v).  Cells were fixed with 50% (w/v) TCA and stained 
with 0.4% (w/v) sulforhodamine B (SRB) for 30 minutes before washing with 1% (v/v) acetic acid. SRB 
was solubilised with 10 mM Tris pH 10.5, the absorbance read at 570 nM, and cell growth expressed 
as % of the growth of cells exposed to 1% (v/v) DMSO.  The concentration of compound that 
resulted in 50% growth inhibition (GI50) was calculated by interpolation from the growth 
inhibition/concentration curves using GraphPad Prism software (La Jolla, USA).  Combination growth 
inhibition studies of NU6102 and pictilisib were performed as previously described (Haagensen et al, 
2012). 
 
Clonogenic assays 
Cells were seeded into 6-well plates at a density of 1x105/well and allowed to adhere overnight.  The 
GI50 concentration from the SRB assay for the pyrimidine compounds 1-8 was added to the cells for 8 
or 72 hours.  Cells were washed twice with PBS before the addition of standard growth medium. 
Following incubation to allow colony (>50 cells) formation, cells were fixed with Carnoy’s solution 
and stained with 0.4% (w/v) crystal violet solution for 1 hour. Colonies were washed with 1% (v/v) 
acetic acid and counted using an Oxford Optronix Colcount (Oxford, UK).  Single agent and 
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combination cytotoxicity studies with NU6102 and pictilisib at 1 or 10 µM were performed using the 
same method with cells being exposed to drugs for 72 hours before plating out for colony formation. 
Statistical analyses were performed using ANOVA.  
 
Flow cytometry 
Cells were seeded into 6-well plates at a density of 4x105/well and allowed to adhere overnight.  
Incubation of the cells with the GI50 concentration of each compound for up to 24 hours, was 
followed by washing with PBS and cell removal with trypsin.  Trypsinised cells were centrifuged, 
washed with PBS, and fixed with 75% ethanol/25% PBS (v/v) overnight.  Pellets were rehydrated 
with PBS and stained using 1 mg/ml RNase and 400 mg/ml propidium iodide for 4 hours, and 
analysed using a Becton Dickinson FACSscan and Cellquest software (BD biosciences, Oxford, UK) 
with data evaluation using WinMdi software (http://facs.scripps.edu/software.html) and ANOVA 
statistical analysis. 
 
Western blotting 
Cells were seeded into 6-well plates at a density of 4x105/well and allowed to adhere overnight.  
Cells were incubated with 0.5, 5 or 50 µM 1 or 5 for 4, 8 or 24 hours before being washed and 
extracted with Phosphosafe buffer (Merck, Nottingham, UK ).  Protein concentrations were 
determined by bicinchoninic acid assay (Thermo Scientific, Cramlington, UK) and 30 µg of total 
protein for each sample was loaded into the wells of a 4-20% tris-glycine Novex gel (Invitrogen, 
Paisley, UK).  Proteins were resolved at 120 V for approximately 2 hours before being transferred to 
Hybond-C nitrocellulose (GE Healthcare, Chalfont St Giles, UK).  Membranes were probed with the 
appropriate dilution of antibody overnight and, after washing, the appropriate secondary antibody 
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used at a dilution of 1:1000, followed by analysis using Supersignal West Dura enhanced 
chemiluminescence substrate (Thermo Scientific, Cramlington, UK). 
 
In vivo studies 
All of the in vivo experiments were reviewed and approved by the institutional animal welfare 
committee, and performed according to the United Kingdom Coordinating Committee on Cancer 
Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (second edition) 
and national law.  CD-1 nude mice (Charles River, Ramsgate, Kent, UK) were implanted with 1 x 107 
HT29 cells, in a mixture of Matrigel/RPMI cell culture media (1:1 v/v), subcutaneously on the right 
flank.  Tumours were allowed to develop until they were palpable (approximately 0.5 x 0.5 cm, 10–
12 days after implantation) and randomised into 4 treatment groups (6 animals/group).  Mice were 
treated with vehicle (control), NU6301 120 mg/kg i.p. (a water soluble prodrug of NU6102 (Thomas 
et al, 2011); 120 mg/kg NU6301 being equivalent to 100 mg/kg NU6102) twice daily, 100 mg/kg 
pictilisib p.o. once daily, or the combination of twice daily NU6301 (120 mg/kg i.p.) and once daily 
pictilisib (100 mg/kg p.o.) for 10 days.  Tumour volume was calculated from two-dimensional calliper 
measurements using the equation a2 x b/2, where a is the smallest measurement and b the largest. 
Data are presented as median relative tumour volumes (RTV), where the tumour volume on the 
initial day of treatment (day 0) is assigned an RTV value of 1 in accordance with the formula: RTV = 
tumour volume on day of observation/tumour volume on day 0.  Statistical analyses of the effects of 
drug treatment was undertaken using the Mann-Whitney test. 
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Results 
The structures of the compounds tested are shown in Supplementary Figure 1 and their 
activity as inhibitors of CDK2, the four PI3K isoforms and mTOR in purified kinase assays is shown in 
Table 1; ranked in order of potency as inhibitors of CDK2.  Sulfonamide 1 is an extremely potent 
inhibitor of CDK2 (IC50 0.1 nM) and a low µM inhibitor of all of the PI3K isoforms with the exception 
of PI3Kβ.   However, 1 did not inhibit mTOR at the highest concentration tested (20 µM).  The parent 
compound in this series, 2, inhibited CDK2 and all of the PI3K isoforms at similar concentrations (1-
10 µM), but was somewhat less potent against mTOR. The cyano compound 7 has IC50 values in the 
range 10-20 µM for CDK2 and the PI3Kα, δ and γ isozymes, but like 1 is less active against PI3Kβ and 
mTOR.  The nitroso compound 6 is similar to 7, although somewhat less active against CDK2 and 
more active against PI3Ks α, δ and γ.  The aldehyde 4 and cyano compound 5 are similar to 6, 
although 4 is distinct in having an IC50 for mTOR of 15 µM, versus <5% inhibition for 6 and 5 at 20 
µM.  Also, 5 is less active than 6 and 4 against CDK2.  Importantly, the O4-(4-chlorobenzyl) compound 
8 did not inhibit CDK2 but is an inhibitor of all four PI3K isozymes and mTOR, whereas 3 is only active 
against mTOR (IC50 13 µM). 
The cell growth inhibitory activity of each compound was tested using the SRB assay in 
HCT116 and HT29 cells.  GI50 values were calculated from the mean of 3 separate assays for each 
compound, and are given in Table 2.  Rapamycin, dactolisib (NVP-BEZ235), pictilisib (GDC-0941; 
pictrelisib) and NU6102 were used as positive controls for mTOR inhibition, dual PI3K and mTOR 
inhibition, pan PI3K inhibition and CDK2 inhibition, respectively. Compounds 1, 2 and 5 were 
equipotent in both cell lines, similar in potency to rapamycin, but markedly less potent than the dual 
PI3K/mTOR inhibitor dactolisib. Inhibitors 4, 7 and 8 also had similar GI50 values, but were 5-10-fold 
less potent at inhibiting cell growth than 1, 2 and 5.  Growth inhibition induced by 3 and 6 did not 
reach 50% at 100 µM, inducing a maximum of 35% reduction in growth at 100 µM in HCT116 cells. 
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The effects of the compounds on cell cycle phase distribution at GI50 concentrations, or at 
100 µM for 6 and 3, in asynchronous cultures were evaluated by flow cytometry in HCT116 cells 
(Figure 1A).  An increase in the G1 population was observed, of varying magnitude, with 2, 4 and 5 
producing greater G1 phase accumulation than rapamycin or dactolisib (NVP-BEZ235).  No effect on 
cell cycle phase distribution was observed with 100 µM 3.  Compound 1 was unique in inducing the 
formation of a sub-G1 fraction, indicative of apoptosis (Figure 1).  Further analysis of the effect of 1 
on the cell cycle indicated that the sub-G1 fraction became apparent from 3 hours onwards in 
HCT116 cells (Figure 1B).  The increase in the sub-G1 fraction was significant after 3 hours (p=0.013) 
and remained significant up to 8 hours (p<0.002).  The G1 fraction was reduced after 4 hours 
exposure to 1, but was only significant at the 10% level (p<0.09), whereas the S phase fraction was 
significantly reduced at 4 hours (p<0.016).  The increase in the G2/M phase fraction was significant 
at both 4 and 6 hours (p<0.011).  In HT29 cells, 1 induced a time-dependent increase in the G2/M 
fraction, with a sub-G1 fraction becoming apparent from 6 hours onwards (Figure 1C) which was 
concentration-dependent at 24 hours (Supplementary Figure 2).  Although a sub-G1 fraction was 
apparent at 6 and 8 hours, this was not significant (p=0.183 at 8 hours); whereas the G1 fraction was 
significantly reduced after 4 hours (p<0.002).  The S-phase fraction in HT29 cells was significantly 
reduced after 6 hours (p<0.04) treatment with 1, and the G2/M fraction was significantly increased 
after 4 hours (p<0.002). 
To determine whether the sub-G1 fraction observed following treatment with 1 reflected 
cytotoxicity, clonogenic survival assays were performed in HCT116 and HT29 cells following an 8 
hour exposure.  Compound 1 reduced the clonogenic survival of cells in a concentration dependent 
manner in both HCT116 and HT29 cells (Figure 2A-B), with 50% inhibition of colony formation at 5 
µM.  Consistent with the lack of a sub-G1 peak in flow cytometry experiments, the other pyrimidine 
inhibitors were not cytotoxic in either cell line even after 72 hours exposure (HCT116 cells; Figure 
2C).  
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To explore the contribution of CDK2 inhibition to the cytotoxicity of 1, the effects of 1 and 5 
on target protein phosphorylation were examined in HCT116 (Figure 3) and HT29 (Supplementary 
Figure 3) cells following 4, 8 and 24 hour exposure.  Compound 5 was selected as being equipotent 
to 1 against PI3Ks and mTOR, with similar growth inhibitory potency in both cell lines but 600,000-
fold less active against CDK2 (Tables 1 and 2).  Compound 1 induced concentration-dependent 
inhibition of Rb phosphorylation in HCT116 cells, with inhibition at a GI50 concentration of 5 µM 
being observed at all time points, and at 24 hours in HT29 cells.  In contrast, the effect of 5 on Rb 
phosphorylation was less pronounced and only clearly observed after 24 hours exposure to 50 µM.   
Compounds 1 and 5 had similar effects on rS6 phosphorylation in both cell lines, and only 5 
consistently reduced AKT phosphorylation at 50 µM. 
The results obtained with compound 1 in comparison to the other compounds suggested 
that dual CDK2 and PI3K inhibition resulted in cytotoxicity, and to confirm this suggestion studies 
were performed with the potent CDK2 inhibitor NU6102 (4-[[6-(cyclohexylmethoxy)-9H-purin-2-
yl]amino]-benzenesulfonamide) (Davies et al, 2002) in combination with the pan-PI3K inhibitor 
pictilisib.  As shown in Figure 4A, the combination of NU6102 and pictilisib was synergistic in growth 
inhibition studies in both the HCT116 and HT29 cell lines.  Furthermore, the combination of the two 
drugs at 10 µM was cytotoxic to HT29 cells, which was significantly enhanced compared to either 
compound alone at this concentration (Figure 4B; p≤0.0001). However, in the HCT116 cell line, there 
was only a significant increase in cytotoxicity with the combination compared to pictilisib alone 
(p≤0.0001), as NU6102 was cytotoxic as a single agent (Figure 4B). 
An in vivo tumour growth inhibition study was performed using the HT29 model treated for 
10 days with the NU6102 prodrug NU6301 at 120mg/kg twice each day (equivalent to 100 mg/kg 
NU6102), pictilisib (GDC-0941) at 100 mg/kg/d or the combination of the two drugs at these doses, 
which were based on in vivo pharmacodynamic data from earlier studies (Haagensen et al, 2013; 
Thomas et al, 2011).  Compound 1 was not suitable for in vivo studies as it contains a 5-nitroso 
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group, which is notoriously metabolically labile and potentially reactive. As shown in Figure 4C, 
relative tumour volumes (RTV) in mice treated with the combination of NU6301 and pictilisib (GDC-
0941) were significantly lower in comparison to either of the drugs alone (p = 0.008 and p = 0.018, 
respectively, Mann Whitney test) at the end of treatment (day 10).  There was no tumour growth in 
the combination group while on treatment, whereas single agent treatment at the doses used only 
generated growth delays which were not significant in the case of NU6301 alone (time to RTV4 
versus control – p = 0.13, Mann Whitney test), and not highly significant in the case of pictilisib (GDC-
0941; time to RTV4 versus control – p = 0.026, Mann Whitney test).  In contrast, growth delay was 
highly significant for the combination therapy (time to RTV4 versus control – p = 0.0043, Mann 
Whitney test).  Although a formal toxicology study was not performed, the combination treatment 
was well tolerated with no consistent impact of single agent or combination drug treatment on body 
weights or clinical condition. 
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Discussion 
Inhibitors of mTOR, PI3K and CDK2 are currently in various stages of clinical development.  
Extensive preclinical studies indicate that combinations of targeted agents may demonstrate greater 
anti-tumour activity and selectivity than single agents, the combination of PI3K and MEK inhibitors 
being an excellent example (Engelman et al, 2008; Haagensen et al, 2012; Haagensen et al, 2013).  
Counter-screening of compounds synthesised to target CDK2 identified a number of pyrimidines that 
were able to inhibit PI3K and/or mTOR, and we evaluated inhibitors with a range of potencies 
against CDK2, PI3K and mTOR for their effects on cell growth, cell cycle phase distribution and 
cytotoxicity. 
In the two colorectal cancer cell lines studied, HCT116 and HT29, three of the compounds 
had GI50 values of < 20 µM: 1, 2 and 5.  The wide range of potencies of these compounds as 
inhibitors of CDK2 (0.1, 2,200 and 60,000 nM, respectively) and the lack of activity against mTOR of 
two of the compounds (< 5% inhibition at 20 µM: 1 and 5), yet similar potency for PI3K inhibition, is 
not inconsistent with growth inhibition being due to activity against the latter targets.  The reduced 
growth inhibitory properties on 4, 6, 7 and 8, despite similar potency against PI3Ks to 1, 2 and 5, may 
be due to reduced cellular uptake resulting from the major structural changes at the 4-position 
(replacement of the cyclohexylmethyl group in 6, 7,  8) or 5-position (replacement of the nitroso 
group with formyl  in 4).  In this latter regard, removal of the 5-nitroso group (3) resulted in 
complete loss of activity against CDK2 and PI3Ks; however, interestingly, modest mTOR inhibition 
was retained.  Nevertheless, despite the mTOR inhibitory activity of 3, the compound did not inhibit 
cell growth.  The reason for the lack of CDK2 inhibition by 3 can be explained by the absence of an 
intra-molecular hydrogen bond as in 1 (i.e. between the 5-nitroso and the 6-amino group), which is 
critical for maintaining the correct orientation of the 6-amino group for hydrogen bonding to Glu-81 
of CDK2 (Arris et al, 2000).  A similar effect may explain the lack of activity of 3 against PI3Ks, 
although there are no structural data to support this contention. 
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When asynchronous cell cultures were treated with GI50 concentrations of the growth 
inhibitory compounds the predominant effect was an accumulation of cells in the G1 phase of the 
cell cycle.  Both rapamycin and dactolisib (NVP-BEZ235) also caused a G1 arrest at their GI50 
concentrations, an effect that has been previously reported with PI3K and/or mTOR inhibitors (Mita 
et al, 2003; Serra et al, 2008).  In contrast to the other growth inhibitory compounds, 1 initially 
either had no effect on the fraction of cells in the G1 phase (HCT116) or reduced the size of the G1 
fraction (HT29), before rapidly (≤ 6  hours) inducing a sub-G1 population in both cell lines indicative 
of apoptosis, although only significantly in the HCT116 cells.  The impact of the apoptosis induced by 
1 was revealed by clonogenic cytotoxicity studies where the compound was shown to be cytotoxic to 
both HCT116 and HT29 cells following exposure for 8 hours at growth inhibitory concentrations.  In 
marked contrast, exposure of HCT116 cells for 72 hours to all of the other pyrimidines failed to 
induce significant cytotoxicity.  Together, these cellular data suggest that the potent CDK2 inhibitory 
activity of 1 contributes to the cytotoxic activity of the compound. 
To evaluate whether the relative potencies of compounds against purified kinases reflected 
their activity in a cellular context, Western blotting experiments were performed with 1 and the 
non-CDK2 inhibitory control compound, 5.  As expected, 1 inhibited the phosphorylation of the CDK2 
substrate Rb at earlier time points and at lower concentrations than 5, and these data are consistent 
with the hypothesis that the apoptosis and cytotoxicity induced by 1 is related to CDK2 inhibition. 
Interestingly, despite good inhibition of rS6 phosphorylation, compound 1 did not inhibit the 
phosphorylation of AKT, which is likely to reflect phosphorylation at this site by other pathways, for 
example, IKK has recently been implicated in promoting AKT phosphorylation at Ser473 (Dan et al, 
2016).  
To confirm that the cytotoxicity observed with 1 was due to dual CDK2 and PI3K inhibition, 
combination studies were performed with the potent and selective CDK2 inhibitor NU6102 in 
combination with the pan-PI3K inhibitor pictilisib. In growth inhibition studies a synergistic as 
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opposed to an additive interaction was observed, particularly in the HCT116 cell line, and in 
cytotoxicity studies combination of the two inhibitors was markedly more cytotoxic in HT29 cells 
than either compound alone.  Importantly, the superior activity of the combination of the CDK2 and 
the PI3K inhibitor was recapitulated in an in vivo anti-tumour study without any marked increase in 
host toxicity, as evaluated by body weight changes and clinical observations.  The specificity of 
NU6102 as a CDK2 inhibitor has been well-established (Davies et al, 2002) and confirmed 
subsequently in a study using CDK2 WT and KO MEFs (Thomas et al, 2011).  At the concentrations 
and doses of NU6102 used in the current study (10µM in vitro and 100 mg/kg in vivo), these previous 
studies have demonstrated CDK2 specificity (Davies et al, 2002; Thomas et al, 2011).  Pictilisib is a 
very widely used and well-characterised PI3K inhibitor, and was used at doses and concentrations in 
line with previous published studies (Haagensen et al, 2012; Haagensen et al, 2013).  Consequently, 
these tool compounds can be used to show that dual CDK2 and PI3K inhibition may represent an 
approach to improving anti-tumour selectivity with these two classes of targeted agents.  
Mechanistically, the potential of dual CDK2 and PI3K pathway inhibition has been 
highlighted by a number of studies.  Initially, Maddika and colleagues (Maddika et al, 2008) 
demonstrated that nuclear translocation of AKT results in phosphorylation of CDK2/cyclin A, leading 
to cytoplasmic redistribution of CDK2/cyclin A which was required for S to G2-M cell cycle phase 
progression.  Subsequently, a landmark paper (Liu et al, 2014) reported that phosphorylation of AKT 
by CDK2/cyclinA2 at S477/T479 was a critical priming event that precedes AKT activation by 
phosphorylation at the canonical S473 locus, and that by this mechanism CDK2/cyclinA1 activity is a 
prerequisite for the oncogenic activity of AKT and hence more generally the PI3K pathway.  These 
recent mechanistic insights into the interplay between CDK2 and PI3K signalling provide a rationale 
for the improved activity of dual CDK2 and PI3K inhibition described in the current paper.  
Furthermore, the effects of the dual pyrimidine-based inhibitor 1 and combined treatment with the 
selective CDK2 antagonist NU6102 and the pan-PI3K inhibitor pictilisib described here are consistent 
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with the results using alternative small molecule CDK and PI3K inhibitors, and siRNA (Cheng et al, 
2012).  In this latter study, increased apoptosis in vitro and enhanced tumour growth delay in vivo 
were observed when both CDK2 and PI3K, specifically PI3Kα, were modulated by chemical and/or 
molecular genetic means. 
In summary, we have synthesised and characterised a series of 6-aminopyrimidines 
identified from a kinase screen that are inhibitors of PI3K and/or mTOR and/or CDK2.  In HCT116 and 
HT29 cell lines, PI3K inhibition is associated with cell growth inhibition, regardless of activity against 
CDK2.  Likewise, the level of mTOR inhibition does not influence cell growth inhibitory potency.  
Importantly, the mixed CDK2 and PI3K inhibitor 1 induces apoptosis and is cytotoxic, suggesting that 
dual CDK2/PI3K targeting may be preferential to inhibition of either enzyme alone.  Mechanistically 
the recent identification of direct interactions between CDK2 and AKT, the proximal downstream 
target of PI3K signalling, provides a rationale for the simultaneous targeting of the CDK2 and the 
PI3K pathway in order to achieve maximal anti-tumour effects. 
 
Acknowledgements 
 
PI3K and mTOR assays were performed at UCB Celltech and we thank UCB Pharmaceuticals scientists 
Andrew Gill and Tom Crabbe for the development of these assays.  GB, HDT, L-Z W, BTG, IRH, DRN, 
RJG and CC were funded by a CR UK Drug Discovery Programme (C240/A7409), CHR was a PhD 
Student funded by CR UK (C8120/A8000), SLP was funded by a CR UK Medicinal Chemistry Training 
Programme (C129/A6963) and EJH was an MRC CASE Award PhD Student supported by UCB 
Celltech. 
  
Dual PI3K/CDK2 inhibition enhances anti-tumour activity 
18 
 
References 
Aleem E, Berthet C, Kaldis P (2004) Cdk2 as a master of S phase entry: fact or fake? Cell Cycle 3(1): 
35-7 
 
Arris CE, Boyle FT, Calvert AH, Curtin NJ, Endicott JA, Garman EF, Gibson AE, Golding BT, Grant S, 
Griffin RJ, Jewsbury P, Johnson LN, Lawrie AM, Newell DR, Noble ME, Sausville EA, Schultz R, Yu W 
(2000) Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct 
molecular interactions and tumor cell growth inhibition profiles. J Med Chem 43(15): 2797-804 
 
Asghar U, Witkiewicz AK, Turner NC, Knudsen ES (2015) The history and future of targeting cyclin-
dependent kinases in cancer therapy. Nat Rev Drug Discov 14(2): 130-46 
 
Brachmann S, Fritsch C, Maira SM, Garcia-Echeverria C (2009) PI3K and mTOR inhibitors: a new 
generation of targeted anticancer agents. Current opinion in cell biology 21(2): 194-8 
 
Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, Jen J, Isaacs WB, Bova GS, 
Sidransky D (1997) Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 
57(22): 4997-5000 
 
Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines 
human glioblastoma genes and core pathways. Nature 455(7216): 1061-8 
 
Celebi JT, Shendrik I, Silvers DN, Peacocke M (2000) Identification of PTEN mutations in metastatic 
melanoma specimens. Journal of medical genetics 37(9): 653-7 
 
Cheng CK, Gustafson WC, Charron E, Houseman BT, Zunder E, Goga A, Gray NS, Pollok B, Oakes SA, 
James CD, Shokat KM, Weiss WA, Fan QW (2012) Dual blockade of lipid and cyclin-dependent 
kinases induces synthetic lethality in malignant glioma. Proc Natl Acad Sci U S A 109(31): 12722-7 
 
Chiarini F, Evangelisti C, McCubrey JA, Martelli AM (2015) Current treatment strategies for inhibiting 
mTOR in cancer. Trends Pharmacol Sci 36(2): 124-35 
 
Condliffe AM, Davidson K, Anderson KE, Ellson CD, Crabbe T, Okkenhaug K, Vanhaesebroeck B, 
Turner M, Webb L, Wymann MP, Hirsch E, Ruckle T, Camps M, Rommel C, Jackson SP, Chilvers ER, 
Stephens LR, Hawkins PT (2005) Sequential activation of class IB and class IA PI3K is important for 
the primed respiratory burst of human but not murine neutrophils. Blood 106(4): 1432-40 
Dual PI3K/CDK2 inhibition enhances anti-tumour activity 
19 
 
 
Dan HC, Antonia RJ, Baldwin AS (2016) PI3K/Akt promotes feedforward mTORC2 activation through 
IKKalpha. Oncotarget: [ePub ahead of print] 
 
Davies TG, Bentley J, Arris CE, Boyle FT, Curtin NJ, Endicott JA, Gibson AE, Golding BT, Griffin RJ, 
Hardcastle IR, Jewsbury P, Johnson LN, Mesguiche V, Newell DR, Noble ME, Tucker JA, Wang L, 
Whitfield HJ (2002) Structure-based design of a potent purine-based cyclin-dependent kinase 
inhibitor. Nature structural biology 9(10): 745-9 
 
Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat 
Rev Cancer 9(8): 550-62 
 
Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, 
Song Y, Chirieac LR, Kaur R, Lightbown A, Simendinger J, Li T, Padera RF, Garcia-Echeverria C, 
Weissleder R, Mahmood U, Cantley LC, Wong K-K (2008) Effective use of PI3K and MEK inhibitors to 
treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14(12): 1351-1356 
 
Garcia JM, Silva JM, Dominguez G, Gonzalez R, Navarro A, Carretero L, Provencio M, Espana P, 
Bonilla F (1999) Allelic loss of the PTEN region (10q23) in breast carcinomas of poor 
pathophenotype. Breast Cancer Res Treat 57(3): 237-43 
 
Haagensen EJ, Kyle S, Beale GS, Maxwell RJ, Newell DR (2012) The synergistic interaction of MEK and 
PI3K inhibitors is modulated by mTOR inhibition. Br J Cancer 106(8): 1386-1394 
 
Haagensen EJ, Thomas HD, Wilson I, Harnor SJ, Payne SL, Rennison T, Smith KM, Maxwell RJ, Newell 
DR (2013) The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates 
with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing mice. PLoS One 8(12): 
e81763 
 
Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC (1999) Cdk phosphorylation triggers 
sequential intramolecular interactions that progressively block Rb functions as cells move through 
G1. Cell 98(6): 859-69 
 
Harrington LS, Findlay GM, Lamb RF (2005) Restraining PI3K: mTOR signalling goes back to the 
membrane. Trends Biochem Sci 30(1): 35-42 
 
Dual PI3K/CDK2 inhibition enhances anti-tumour activity 
20 
 
Lannutti BJ, Meadows SA, Herman SEM, Kashishian A, Steiner B, Johnson AJ, Byrd JC, Tyner JW, 
Loriaux MM, Deininger M, Druker BJ, Puri KD, Ulrich RG, Giese NA (2011) CAL-101, a p110delta 
selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits 
PI3K signaling and cellular viability. Blood 117(2): 591-594 
 
Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema NA, Andritsos LA, Blum KA, Flynn JM, Jones JA, 
Hu W, Moran ME, Mitchell SM, Smith LL, Wagner AJ, Raymond CA, Schaaf LJ, Phelps MA, Villalona-
Calero MA, Grever MR, Byrd JC (2009) Phase II study of flavopiridol in relapsed chronic lymphocytic 
leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 27(35): 
6012-8 
 
Liu P, Begley M, Michowski W, Inuzuka H, Ginzberg M, Gao D, Tsou P, Gan W, Papa A, Kim BM, Wan 
L, Singh A, Zhai B, Yuan M, Wang Z, Gygi SP, Lee TH, Lu KP, Toker A, Pandolfi PP, Asara JM, Kirschner 
MW, Sicinski P, Cantley L, Wei W (2014) Cell-cycle-regulated activation of Akt kinase by 
phosphorylation at its carboxyl terminus. Nature 508(7497): 541-5 
 
Maddika S, Ande SR, Wiechec E, Hansen LL, Wesselborg S, Los M (2008) Akt-mediated 
phosphorylation of CDK2 regulates its dual role in cell cycle progression and apoptosis. Journal of cell 
science 121(Pt 7): 979-88 
 
Marchetti F, Cano C, Curtin NJ, Golding BT, Griffin RJ, Haggerty K, Newell DR, Parsons RJ, Payne SL, 
Wang LZ, Hardcastle IR (2010) Synthesis and biological evaluation of 5-substituted O4-
alkylpyrimidines as CDK2 inhibitors. Org Biomol Chem 8(10): 2397-407 
 
Mayer IA, Arteaga CL (2015) The PI3K/AKT Pathway as a Target for Cancer Treatment. Annual Review 
of Medicine: [Epub ahead of print] 
 
Menon S, Manning BD (2008) Common corruption of the mTOR signaling network in human tumors. 
Oncogene 27 Suppl 2: S43-51 
 
Mesguiche V, Parsons RJ, Arris CE, Bentley J, Boyle FT, Curtin NJ, Davies TG, Endicott JA, Gibson AE, 
Golding BT, Griffin RJ, Jewsbury P, Johnson LN, Newell DR, Noble ME, Wang LZ, Hardcastle IR (2003) 
4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2. Bioorg 
Med Chem Lett 13(2): 217-22 
 
Mita MM, Mita A, Rowinsky EK (2003) The molecular target of rapamycin (mTOR) as a therapeutic 
target against cancer. Cancer Biol Ther 2(4 Suppl 1): S169-77 
 
Dual PI3K/CDK2 inhibition enhances anti-tumour activity 
21 
 
Rocca A, Farolfi A, Bravaccini S, Schirone A, Amadori D (2014) Palbociclib (PD 0332991) : targeting 
the cell cycle machinery in breast cancer. Expert opinion on pharmacotherapy 15(3): 407-20 
 
Satyanarayana A, Kaldis P (2009) Mammalian cell-cycle regulation: several Cdks, numerous cyclins 
and diverse compensatory mechanisms. Oncogene 28(33): 2925-39 
 
Sayle KL, Bentley J, Boyle FT, Calvert AH, Cheng Y, Curtin NJ, Endicott JA, Golding BT, Hardcastle IR, 
Jewsbury P, Mesguiche V, Newell DR, Noble ME, Parsons RJ, Pratt DJ, Wang LZ, Griffin RJ (2003) 
Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of 
cyclin-dependent kinases 1 and 2. Bioorg Med Chem Lett 13(18): 3079-82 
 
Serra V, Markman B, Scaltriti M, Eichhorn PJA, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di 
Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J (2008) NVP-BEZ235, a Dual 
PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating 
PI3K Mutations. Cancer Res 68(19): 8022-8030 
 
Shapiro GI (2006) Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 
24(11): 1770-83 
 
Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, 
Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero 
V, Gray JW, Bernards R, Mills GB, Hennessy BT (2008) An integrative genomic and proteomic analysis 
of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68(15): 6084-91 
 
Thomas HD, Wang LZ, Roche C, Bentley J, Cheng Y, Hardcastle IR, Golding BT, Griffin RJ, Curtin NJ, 
Newell DR (2011) Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-
dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301. European journal of 
cancer (Oxford, England : 1990) 47(13): 2052-9 
 
Yap TA, Bjerke L, Clarke PA, Workman P (2015) Drugging PI3K in cancer: refining targets and 
therapeutic strategies. Curr Opin Pharmacol 23: 98-107 
 
  
 
 
 
Dual PI3K/CDK2 inhibition enhances anti-tumour activity 
22 
 
 
  
Dual PI3K/CDK2 inhibition enhances anti-tumour activity 
23 
 
Titles and legends to figures & tables 
 
Figure 1 - Cell cycle phase analysis following exposure to 6-aminopyrimidine inhibitors measured 
by flow cytometry 
A). HCT116 cells were treated with GI50 concentrations of inhibitors (or 100 µM, Table 2) for 24 hours 
then fixed, stained with propidium iodide, and analysed by flow cytometry.  Cell cycle phase 
distribution was analysed by WinMDI software, and the mean cell cycle fraction of cells gated into 
each phase of the cell cycle shown.   B). HCT116 cells were treated with the GI50 concentration of 1 
for up to 8 hours and fixed at time points indicated before being stained with propidium iodide and 
analysed by flow cytometry.  C). HT29 cells were treated with the GI50 concentration of 1 for up to 8 
hours and fixed at the time points shown before being stained with propidium iodide and analysed 
by flow cytometry.  Data are representative of duplicate experiments. 
 
Figure 2 - Effects of 6-aminopyrimidine inhibitors on the clonogenic survival of HCT116 and HT29 
colorectal cancer cells 
A). HCT116 cells were treated with increasing concentrations of 1 for 8 hours.  The medium was 
replaced with normal growth medium and the cells allowed to form colonies for 1 week.  Colonies 
were stained with 0.4% (v/v) crystal violet and counted. B) HT29 cells were treated as described in A.  
C). HCT116 cells were treated with the GI50 concentration (or 100 µM, Table 2) of the 6-
aminopyrimidine inhibitors for 72 hours before being re-plated for analysis of colony formation as 
described in A.  All experiments were performed in triplicate and the data are the mean ± SD. 
 
Figure 3 - Effects of compounds 1 and 5 on the phosphorylation of rS6, AKT and Rb in HCT116 cells 
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HCT116 cells were treated with 1 or 5 for 4, 8 or 24 hours at 0.5, 5 or 50 µM.  Protein was extracted 
and 30 µg resolved on a 4-20% (w/v) tris/glycine SDS PAGE.  Immuno-blotted membranes were 
probed with total and phospho rS6, AKT and Rb antibodies and the Western blots shown are 
representative of at least three experiments. 
 
Figure 4 – The impact of combined CDK2 and PI3K inhibition on colorectal tumour cell growth and 
survival in vitro, and HT29 tumour growth in vivo 
A). HCT116 or HT29 cells were exposed to combinations of NU6102 and pictilisib at fixed ratios 
(0.25x, 0.5x, 1x, 2x and 4x) of their respective GI50 concentrations (NU6102: HCT116 5.7 µM, HT29 13 
µM; pictilisib: HCT116 1.7 µM, HT29 0.25 µM) and cell growth inhibition evaluated by median effect 
analysis.  B). Cytotoxicity of 1 µM or 10 µM NU6102 and pictilisib alone and in combination in 
HCT116 and HT29 colorectal tumour cell lines.  C). Efficacy of the NU6102 pro-drug NU6301 and 
pictilisib, alone and in combination, in HT29 human colorectal tumour xenograft bearing mice.  Mice 
were treated with vehicle (control), NU6301 120 mg/kg i.p. (equivalent to 100 mg/kg NU6102) twice 
daily, 100 mg/kg pictilisib p.o. once daily, or the combination of twice daily NU6301 (120 mg/kg i.p.) 
and once daily pictilisib (100 mg/kg p.o.) for 10 days.  Data are the relative tumour volume (RTV) at 
the end of treatment (day 10) and p values are the statistical differences between the groups as 
indicated by the Mann-Whitney test. 
 
Table 1 – Inhibition of CDK2, PI3K and mTOR kinases by 6-aminopyrimidines 
Values are the IC50 (µM) or the highest concentration tested (µM), and are the mean ± SD or 
individual determinations.  For chemical structures see Supplementary Figure 1. 
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Table 2 – Colorectal tumour cell growth inhibition by 6-aminopyrimidines 
Values are the mean GI50 ± SD, or the highest concentration tested and the % growth inhibition 
observed at that concentration. 
 



C	
B	A		
Compound CDK2 PI3Kα PI3kβ PI3Kδ PI3Kγ mTOR
1
0.0001 ± 
0.00003
3.6, 6.2 >20 3.2, 7.5 3.7, 6.8 >20
2 2.2 ± 0.5 1.3, 2.7 5.7, 11 0.7 , 1.8 1.5, 2.1 19
7 9.6, 13 9.9, 12 >20 12, 14 18, 20 >20
6 7.5, 22 2.9, 4.4 >20 5.0, 6.5 2.9, 7.1 >20
4 22, 24 5.4, 11 >20 2.9, 5.6 1.7, 5.3 15
5 60 ± 10 4.5, 7.7 18, 23 6.9, 5.9 7.5, 12 >20
8 >>10 2.5, 6.2 4.3, 13 0.5, 1.1 1.5, 2.0 4.9
3 >>10 >20 >20 >20 >20 13
Compound GI50 HCT116 (µM) GI50 HT29 (µM)
1 4.3 ± 2.6 12 ± 3
2 6.2 ± 1.8 12 ± 4
7 73 ± 28 >100 µM (30%)
6 >100 µM (35%) >100 µM (1%)
4 64 ± 18 44 ± 5
5 6.7 ± 1.8 14 ± 6
8 52 ± 11 59 ± 20
3 >100 µM (30%) >100 µM (17%)
Dactolisib (NVP-BEZ235) 0.016 ± 0.008 0.014 ± 0.001
Rapamycin 2.3 ± 1.5 4.2 ± 1.4
NU6102 5.7 ± 0.4 13.3 ± 3.4
Pictilisib (GDC-0941) 1.7 ± 0.3 0.25 ± 0.13
